Personal Activity Intelligence in the Treatment of High Blood Pressure

Status Completed

Clinical Trial Summary

Personal Activity Intelligence (PAI) is a novel metric developed to quantify the amount of routine physical activity (PA) needed to improve health and reduce cardiovascular (CV) mortality. The PAI metric can be integrated in PA monitors to promote and track PA. The present pilot study is a 12-week randomized controlled trial designed to test the efficacy of PAI in the treatment of high blood pressure. The primary aim is to investigate how routine PA (expressed as PAI level) affect ambulatory blood pressure by comparing the effect of the intervention (≥100 PAI per week) with a control recommended to follow national PA guidelines. The secondary aims are to investigate the effect on a comprehensive CV risk profile, and to model the effect of PAI level on multiple CV parameters. The CV risk profile includes office BP, arterial stiffness, stroke volume, heart rate, cardiac output, systemic vascular resistance, cardiorespiratory fitness, body composition, blood lipid profile and serum markers of glucose metabolism, kidney failure and systemic inflammation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04151537
Study type	Interventional
Source	Norwegian University of Science and Technology
Contact
Status	Completed
Phase	N/A
Start date	October 21, 2019
Completion date	May 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03708601` - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting	`NCT05503953` - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS	Phase 3
Recruiting	`NCT05526703` - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy	Phase 3
Completed	`NCT06395194` - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension	Phase 3
Not yet recruiting	`NCT06418074` - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity	N/A
Completed	`NCT02890173` - Study of CS-3150 in Patients With Essential Hypertension	Phase 3
Withdrawn	`NCT02096939` - Microvascular Function in Primary Aldosteronism	N/A
Completed	`NCT02944734` - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension	Phase 2
Recruiting	`NCT01956786` - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine	Phase 2/Phase 3
Completed	`NCT02553512` - Helius in Hypertension-I: The UK Hypertension Registry	N/A
Completed	`NCT01198249` - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension	Phase 1
Completed	`NCT01001572` - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension	Phase 3
Recruiting	`NCT00380289` - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension	N/A
Completed	`NCT00139698` - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension	Phase 3
Completed	`NCT00288184` - Uric Acid in Essential Hypertension in Children	Phase 2
Completed	`NCT01289886` - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects	Phase 1
Not yet recruiting	`NCT06041529` - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension	Phase 4
Completed	`NCT04470830` - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed	`NCT00758524` - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension	Phase 2
Recruiting	`NCT05109013` - Juvenile Essential Arterial Hypertension and Vascular Function